--- title: "Biodesix | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 25.56 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285113951.md" datetime: "2026-05-04T20:09:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285113951.md) - [en](https://longbridge.com/en/news/285113951.md) - [zh-HK](https://longbridge.com/zh-HK/news/285113951.md) generator: "portal-rs" --- # Biodesix | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 25.56 M Revenue: As of FY2026 Q1, the actual value is USD 25.56 M, beating the estimate of USD 23.18 M. EPS: As of FY2026 Q1, the actual value is USD -0.81, beating the estimate of USD -1.096. EBIT: As of FY2026 Q1, the actual value is USD -4.609 M. ### Segment Revenue - **Diagnostic Tests Revenue**: Increased by $5,975 thousand, or 37%, to $22,291 thousand for the three months ended March 31, 2026, primarily due to a 29% increase in test volumes and higher average revenue per test, mainly from the Nodify Lung Nodule Risk Assessment testing strategy . - **Development Services Revenue**: Increased by $1,622 thousand, or 99%, to $3,264 thousand for the three months ended March 31, 2026, driven by continued execution on existing contracts and new agreements . ### Operational Metrics - **Gross Margin**: Was 84% in the first quarter of 2026, including a one-time recovery of $0.4 million; excluding this item, the gross margin was 82%, representing a 300-basis-point improvement over the prior-year period . - **Loss from Operations**: Improved by $2,935 thousand, or 32%, to -$6,201 thousand for the three months ended March 31, 2026, from -$9,136 thousand in the prior year period . - **Net Loss**: Improved by $3,308 thousand, or 30%, to -$7,793 thousand for the three months ended March 31, 2026, from -$11,101 thousand in the prior year period . - **Total Operating Expenses**: Increased by $4,662 thousand, or 17%, to $31,756 thousand for the three months ended March 31, 2026, from $27,094 thousand . - **Direct Costs and Expenses**: Increased by $502 thousand, or 14%, to $4,205 thousand, primarily due to increased testing volume . - **Research and Development Expenses**: Increased by $415 thousand, or 14%, to $3,285 thousand, mainly due to higher internal expenses and increased external costs associated with clinical trials . - **Sales, Marketing, General and Administrative Expenses**: Increased by $3,813 thousand, or 19%, to $24,261 thousand, primarily due to increased internal and external costs for sales and marketing activities . - **Impairment Loss on Intangible Assets**: Decreased by $68 thousand, or -93%, to $5 thousand . - **Interest Expense**: Increased by $292 thousand, or 17%, to -$1,977 thousand, primarily due to drawing the Tranche C loan of $10.0 million . - **Other Income, Net**: Increased by $287 thousand, or 293%, to $385 thousand, primarily related to interest and other income . - **Share-Based Compensation Expense**: Increased by $143 thousand, or 15%, to $1,115 thousand . ### Cash Flow - **Net Cash Flows Used in Operating Activities**: -$10,168 thousand for the three months ended March 31, 2026, compared to -$8,602 thousand for the same period in 2025, primarily due to unfavorable changes in net working capital . - **Net Cash Used in Investing Activities**: -$144 thousand for the three months ended March 31, 2026, compared to -$137 thousand for the same period in 2025 . - **Net Cash Provided by Financing Activities**: $16,897 thousand for the three months ended March 31, 2026, compared to $97 thousand for the same period in 2025, including $17.2 million in gross proceeds from common stock issuance . ### Unique Metrics - **Medicare Revenue Contribution**: Accounted for 32% of total revenue for the three months ended March 31, 2026, down from 36% in the prior year . - **Cash and Cash Equivalents**: $25,572 thousand as of March 31, 2026, an increase of 35% over $18,987 thousand as of December 31, 2025 . - **Available Capacity (2024 ATM Program)**: $25.5 million remained available for share issuances as of March 31, 2026 . ### Future Outlook and Strategy Biodesix, Inc. anticipates achieving continued operating leverage as its expanded sales team enhances productivity and performance . The company plans to invest in research and development to foster innovation and create new clinically relevant tests . Additionally, sales and marketing expenses are expected to rise as Biodesix, Inc. expands its sales force and marketing efforts to boost awareness and adoption of its tests . ### Related Stocks - [BDSX.US](https://longbridge.com/en/quote/BDSX.US.md) ## Related News & Research - [Biodesix to present at Canaccord Genuity Annual Growth Conference](https://longbridge.com/en/news/294802503.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md) - [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md) - [SelectQuote Q4 2026 Earnings Preview](https://longbridge.com/en/news/296823343.md) - [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**